Year-over-year earnings per share growth for the last twelve months: Sonnet BioTherapeutics (SONN)

Sonnet BioTherapeutics Holdings (SONN) - corporate logo

The resilience of Sonnet BioTherapeutics (SONN) is based on the safety of its solid tumor therapy and the effectiveness of the FHAB platform. The quarterly EPS growth rate confirms this trend, with the metric recorded at 83.60. Pragmatic management is focused on developing drug delivery systems, while the future sales of bispecific drugs depend on clinical trial outcomes amid high demand.

Sonnet BioTherapeutics Holdings, Inc. (SONN) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 12/13/2025

Comprehensive metric breakdowns and analytics for Sonnet BioTherapeutics Holdings (SONN)

Comprehensive company analysis:Sonnet BioTherapeutics, SONN
Manufactured product of sonnetbio.com

For the biotech startup Sonnet BioTherapeutics (SONN), which develops cancer immunotherapy platforms, earnings per share dynamics reflect the efficiency of capital management prior to drug commercialization. By analyzing quarterly EPS growth estimates, investors can track the percentage change in net income, allowing them to differentiate stable operational resilience from stagnation and the long-term risk of opportunity cost.

Competitors of Sonnet BioTherapeutics

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months januxrx.com|Year-over-year net earnings per share growth for the last 12 months arcusbio.com (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc (ZYME)|Year-over-year net earnings per share growth for the last 12 months Tango Pharma TNGX|Iovance Biotherapeutics Inc - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics Biotechnologies IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (compasstherapeutics.com) - Year-over-year earnings per share growth for the last 12 months|Replimune Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Lyell Immunopharma Inc (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma)|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immix Biopharma|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|cuebiopharma.com (CUE) - Quarterly EPS earnings growth|PDSB (PDS Biotechnology Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIA Biotech|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Inc - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Earnings per share growth in annualized terms for the last twelve months|Intensity Therapeutics Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months senseibio.com SNSE|TOVX: Quarterly EPS earnings growth|Gritstone bio Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KA|Year-over-year earnings per share growth for the last 12 months NEXI (NexImmune, Inc.)|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics Corporation (TSBX)|Year-over-year net earnings per share growth for the last 12 months Vaccinex VCNX|Year-over-year earnings per share growth for the last twelve months harpoontx.com HARP